<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1" specific-use="sps-1.9" article-type="review-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">dic</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia Imagem cardiovascular</journal-title>
        
        <abbrev-journal-title abbrev-type="publisher">Arq Bras Cardiol: Imagem cardiovasc</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2675-312X</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
        
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">2318-8219.20190048</article-id>
      <article-id pub-id-type="doi">10.5935/2318-8219.20190048</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>PET-CT <sup>18</sup>F-FDG applications in cardiac tumors</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Aplicações da PET-TC <sup>18</sup>F-FDG nos tumores cardíacos</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group><contrib contrib-type="author"><name><surname>Brandão</surname><given-names>Simone Cristina Soares</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dompieri</surname><given-names>Luca Terracini</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group>
      <aff id="aff1"><label>1</label><institution content-type="normalized"/><institution content-type="orgdiv1">Hospital das Clínicas</institution><institution content-type="orgname">Universidade Federal de Pernambuco</institution><country country="BR"/><institution content-type="original">Serviço de Medicina Nuclear, Hospital das Clínicas, Universidade Federal de Pernambuco;</institution></aff>
      <aff id="aff2"><label>2</label><institution content-type="normalized"/><institution content-type="orgdiv1">Faculdade de Medicina</institution><institution content-type="orgname">Universidade Federal de Pernambuco</institution><addr-line><named-content content-type="city">Recife</named-content><named-content content-type="state">PE</named-content></addr-line><country country="BR">Brazil</country><institution content-type="original">Faculdade de Medicina, Universidade Federal de Pernambuco, Recife (PE) − Brazil.</institution></aff>
      <author-notes> <corresp id="c01"> Mailing Address: Simone Cristina Soares Brandão • Av. Beira Rio, 360, Apto 201. Ilha do Retiro, Recife – PE. Brazil. CEP: 50750-400 E-mail: <email>sbrandaonuclearufpe@gmail.com</email> </corresp> <fn fn-type="con"> <p>Authors’ contribution</p> <p>Data acquisition: Brandão S, Dompieri L. Data analysis and interpretation: Brandão S, Dompieri L. Manuscript writing: Dompieri L. Critical revision of the manuscript for important intellectual content: Brandão S.</p></fn> <fn fn-type="conflict"> <p>Conflict of interest</p> <p>The authors declare that there is no conflict of interest regarding this manuscript.</p></fn> </author-notes>
			<pub-date date-type="pub" publication-format="electronic">
				<day>14</day>
				<month>01</month>
				<year>2022</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic">
        <season>Oct-Dec</season>
        <year>2019</year>
      </pub-date>
      <volume>32</volume>
      <issue>4</issue>
      <fpage>309</fpage>
      <lpage>317</lpage>
      <history><date date-type="received"><day>18</day><month>4</month><year>2019</year></date><date date-type="rev-recd"><day>18</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>1</day><month>7</month><year>2019</year></date></history>
      <permissions>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
<license-p>
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p>
</license>
</permissions>
      <abstract><title>ABSTRACT</title><p>Cardiac neoplasms are divided into primary and secondary. Secondary neoplasms are 20 to 40 times more common than the primary ones. Although rare, primary cardiac neoplasms may be benign or malignant. Benign neoplasms are responsible for 75% of the cases. The main objectives of cardiovascular imaging are to define tumor morphology and etiology, identify potential complications and assist in the establishment of treatment. For the diagnosis of cardiac neoplasms, positron emission tomography combined with computed tomography (PET-CT) with fluorodeoxyglucose-F18 (<sup>18</sup>F-FDG) is a technique that is still little used, especially in primary cardiac tumors. However, it can help differentiate between malignant and benign tumors, thus preventing cardiac biopsies and unnecessary invasive treatments. For this review, we searched the PubMed database, considering the publications on this topic in the past 10 years. PET-CT <sup>18</sup>F-FDG is a useful test to differentiate benign from malignant heart masses according to the higher degree of glycolytic metabolism found in malignant neoplasms. Moreover, in malignant tumors, PET-CT <sup>18</sup>F-FDG plays a central role in disease staging and may help assess treatment response.</p></abstract>
      <trans-abstract xml:lang="pt"><title>Resumo</title><p>As neoplasias cardíacas são divididas em primárias e secundárias. As secundárias são 20 a 40 vezes mais comuns do que as primárias. Embora raras, as neoplasias cardíacas primárias podem ser benignas e malignas, sendo as benignas responsáveis por 75% dos casos. Os principais objetivos da imagem cardiovascular são definir a morfologia e etiologia do tumor, identificar potenciais complicações e auxiliar na definição de tratamento. Para o diagnóstico de neoplasias cardíacas, a tomografia por emissão de pósitrons acoplada à tomografia computadorizada (PET-TC) com a fluordesoxiglicose-F<sup>18</sup> (<sup>18</sup>F-FDG) é uma técnica ainda pouco utilizada, principalmente nos tumores cardíacos primários. Entretanto, ela pode ajudar na diferenciação entre tumores malignos e benignos e, assim, evitar biópsias cardíacas e tratamentos invasivos desnecessários. Para esta revisão,realizamos pesquisa na base de dados PubMed, considerando as publicações sobre o tema nos últimos 10 anos. A PET-TC <sup>18</sup>F-FDG é um exame útil para diferenciar massas cardíacas benignas das malignas, de acordo com o maior grau de metabolismo glicolítico encontrado nas neoplasias malignas. Além do mais, nos tumores malignos, a PET-TC <sup>18</sup>F-FDG tem papel central no estadiamento da doença e pode ajudar na avaliação de resposta ao tratamento.</p></trans-abstract>
      <kwd-group xml:lang="en"><kwd>Heart Neoplasms</kwd><kwd>Review</kwd><kwd>Positron-Emission Tomography</kwd></kwd-group>
      <kwd-group xml:lang="pt"><kwd>Tumores Cardíacos</kwd><kwd>Revisão</kwd><kwd>Tomografia por Emissão de Pósitrons</kwd></kwd-group>
      <counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="0"/><page-count count="9"/></counts>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
